"Number of ADSs outstanding on a fully diluted basis as of June 30, 2021 was 12,584,362 (or 251,687,240 ordinary shares) which includes 699,806 ADSs (or 13,996,120 ordinary shares) sold during the quarter ended June 30, 2021 under the Company's ATM program"
https://finance.yahoo.com/news/chemomab-therapeutics-announces-second-quarter-120000199.html
Recent CMMB News
- Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/12/2024 08:02:17 PM
- Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences • GlobeNewswire Inc. • 05/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 11:00:40 AM
- Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:05:07 AM
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis • GlobeNewswire Inc. • 03/25/2024 11:06:46 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 12:00:10 PM
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/07/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference • PR Newswire (US) • 03/05/2024 12:00:00 PM
- Biotech Shares Massively Bid Up Before Opening Bell • AllPennyStocks.com • 02/20/2024 02:20:00 PM
- Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update • PR Newswire (US) • 02/14/2024 12:00:00 PM
- Chemomab Therapeutics to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/05/2024 12:00:00 PM
- Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:00:16 PM
- Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 • PR Newswire (US) • 01/03/2024 12:00:00 PM
- Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis • PR Newswire (US) • 11/16/2023 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/15/2023 09:35:45 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM